In 24 patients (23 evaluable) with skin chronic graft-versus-host disease after transplant, ruxolitinib 1·5% cream on one body side cut affected skin area from 14·3% to 6·2% at day 28 vs 14·5% to 10·4% with placebo cream on the other side (difference −4·2 points).
RCTn = 24
Markova et al. Topical ruxolitinib for chronic cutaneous graft-versus-host disease: a single-centre, randomised, double-blind, intra-patient-controlled phase 2 trial